19 completed, 3 not yet recruiting, 2 recruiting, 1 active not recruiting. 14 Phase 3, 7 Phase 2, 2 Not applicable, 2 Phase 4, 1 Phase 1.
Follow Primary Immunodeficiency Diseases (PID): new trials by email Literature Review of Primary Immunodeficiency Diseases (PID) trials Research Report on Primary Immunodeficiency Diseases (PID)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TAK-664 in People With Primary Immunodeficiency Diseases Who Have Not Yet Been Treated With Immunoglobulins TAK-664 - Primary Immunodeficiency Diseases (PID) | Phase 4 | Not yet recruiting | Takeda | 9 | 2026-11-01 | 2026-09-08 |
| Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients IVIG-VImmune, IVIG-Immuglo - Primary Immunodeficiency Diseases (PID) | Phase 3 | Not yet recruiting | Virchow Group | 44 | 2025-07-01 | 2025-06-12 |
| A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency Immune Globulin Subcutaneous (Human), 20% Solution - Primary Immunodeficiency Diseases (PID) | Recruiting | Takeda | 100 | 2025-02-17 | 2026-08-07 | |
| Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study Inborn errors of immunity, A. Routine .1CBC with blood film. .2Liver Function Test. .3Kidney Function Test. 4. Inflamatory marker ESR, CRP B.Immunology 1-Immunoglobulins IgG, IgM, IgA, IgE 2-Flow cytometric assessment: B - Primary Immunodeficiency Diseases (PID) | Not yet recruiting | Assiut University | 60 | 2025-01-05 | 2024-10-21 | |
| Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders blood sampling - Primary Immunodeficiency Diseases (PID) | Not applicable | Recruiting | prof. dr. Rik Schrijvers | 20 | 2024-11-21 | 2025-12-03 |
| A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases TAK-881, Koru 24 G HIgH Flo Subcutaneous Safety Needle Set (investigational in the US) - Primary Immunodeficiency Diseases (PID) | Phase 3 | Active not recruiting | Takeda | 53 | 2024-11-04 | 2026-04-08 |
| Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency Virtual reality video watching, Tablet video watching - Primary Immunodeficiency Diseases (PID) | Not applicable | Completed | Dr. Hatice Dönmez | 31 | 2024-09-15 | 2026-06-09 |
| At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill No Intervention - Primary Immunodeficiency Diseases (PID) | Completed | Takeda | 22 | 2023-12-27 | 2025-06-13 | |
| A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases TAK-881, HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Takeda | 65 | 2023-10-24 | 2026-09-30 |
| A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants TAK-771 - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Takeda | 15 | 2022-09-13 | 2026-05-19 |
| Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies Cutaquig - Primary Immunodeficiency Diseases (PID) | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 100 | 2022-09-01 | 2023-08-14 | |
| A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) TAK-771 - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Takeda | 16 | 2022-01-24 | 2024-11-25 |
| A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID) Immune Globulin Intravenous (IGIV), Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Baxalta now part of Shire | 17 | 2020-08-11 | 2024-03-22 |
| Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) CUVITRU - Primary Immunodeficiency Diseases (PID) | Completed | Baxalta now part of Shire | 126 | 2018-09-24 | 2021-03-05 | |
| Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects HYQVIA - Primary Immunodeficiency Diseases (PID) | Phase 3 | Completed | Baxalta now part of Shire | 44 | 2017-09-25 | 2023-10-23 |
| Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects HYQVIA, KIOVIG, Cuvitru - Primary Immunodeficiency Diseases (PID) | Phase 4 | Completed | Baxalta now part of Shire | 42 | 2017-05-30 | 2023-01-11 |
| Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) HYQVIA - Primary Immunodeficiency Diseases (PID) | Completed | Baxalta now part of Shire | 264 | 2015-11-12 | 2022-10-18 | |
| Phase 2/3 Study of IGSC, 20% in PIDD Immune Globulin Intravenous (Human), 10% Solution, Immune Globulin Subcutaneous (Human), 20% Solution - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 86 | 2013-01-28 | 2021-07-20 |
| Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 54 | 2011-12-29 | 2021-05-19 |
| Immune Globulin Subcutaenous (Human), 20% Immune Globulin Subcutaneous (Human), 20%, Immune Globulin Intravenous (Human), 10%, Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) - Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 55 | 2011-06-20 | 2021-05-05 |
Showing 20 of 26. Sign in to see all of them.
Primary Immunodeficiency Diseases (26) · Agammaglobulinemia (1) · Immunologic Deficiency Syndromes (1) · Mucocutaneous Lymph Node Syndrome (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (26) · Genetic Diseases, Inborn (26) · Immune System Diseases (26) · Immunologic Deficiency Syndromes (25) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Lymphatic Diseases (2) · Autoimmune Diseases (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Cytopenia (1) · Hemorrhage (1) · Hemorrhagic Disorders (1)
gamma-Globulins (12) · Solutions (8) · Hizentra (3) · Blood Specimen Collection (1) · Detergents (1) · Patents as Topic (1) · Safety (1) · Single Person (1) · Solvents (1) · Therapeutics (1)
Baxalta now part of Shire (14) · Takeda (7) · Assiut University (1) · Dr. Hatice Dönmez (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Virchow Group (1) · prof. dr. Rik Schrijvers (1)
United States (12) · Japan (4) · Canada (3) · Czechia (3) · Denmark (3) · Slovakia (3) · Sweden (3) · Germany (2) · Greece (2) · Hungary (2) · Poland (2) · Spain (2) · United Kingdom (2) · Austria (1) · Belgium (1)
Anna Shcherbina, MD,Phd (1) · Rik Schrijvers, MD, PhD (1)
PMID 34931880, PMID 27220317, PMID 30626238, PMID 31268374, PMID 34036490, PMID 21424824, PMID 22846381, PMID 27582171, PMID 27613250, PMID 31228628, PMID 32086639, PMID 35748970, PMID 35934726, PMID 39289739, PMID 41937917
2016 (1), 2023 (1)